GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoSec Medical Inc (FRA:ONMA) » Definitions » Gross Margin %

OncoSec Medical (FRA:ONMA) Gross Margin % : 0.00% (As of Jan. 2023)


View and export this data going back to 2015. Start your Free Trial

What is OncoSec Medical Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. OncoSec Medical's Gross Profit for the three months ended in Jan. 2023 was €0.00 Mil. OncoSec Medical's Revenue for the three months ended in Jan. 2023 was €0.00 Mil. Therefore, OncoSec Medical's Gross Margin % for the quarter that ended in Jan. 2023 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for OncoSec Medical's Gross Margin % or its related term are showing as below:


FRA:ONMA's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.605
* Ranked among companies with meaningful Gross Margin % only.

OncoSec Medical had a gross margin of N/A% for the quarter that ended in Jan. 2023 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for OncoSec Medical was 0.00% per year.


OncoSec Medical Gross Margin % Historical Data

The historical data trend for OncoSec Medical's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoSec Medical Gross Margin % Chart

OncoSec Medical Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

OncoSec Medical Quarterly Data
Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of OncoSec Medical's Gross Margin %

For the Biotechnology subindustry, OncoSec Medical's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoSec Medical's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoSec Medical's Gross Margin % distribution charts can be found below:

* The bar in red indicates where OncoSec Medical's Gross Margin % falls into.



OncoSec Medical Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

OncoSec Medical's Gross Margin for the fiscal year that ended in Jul. 2022 is calculated as

Gross Margin % (A: Jul. 2022 )=Gross Profit (A: Jul. 2022 ) / Revenue (A: Jul. 2022 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

OncoSec Medical's Gross Margin for the quarter that ended in Jan. 2023 is calculated as


Gross Margin % (Q: Jan. 2023 )=Gross Profit (Q: Jan. 2023 ) / Revenue (Q: Jan. 2023 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


OncoSec Medical  (FRA:ONMA) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

OncoSec Medical had a gross margin of N/A% for the quarter that ended in Jan. 2023 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


OncoSec Medical Gross Margin % Related Terms

Thank you for viewing the detailed overview of OncoSec Medical's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoSec Medical Business Description

Traded in Other Exchanges
N/A
Address
24 North Main Street, Pennington, NJ, USA, 08534
OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.

OncoSec Medical Headlines

No Headlines